Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Antiphospholipid syndrome in children
ID
Zajc Avramovič, Mojca
(
Avtor
),
ID
Avčin, Tadej
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(1,07 MB)
MD5: 14F741FFE023363B2C9D900A5E1F65A7
URL - Izvorni URL, za dostop obiščite
https://www.sciencedirect.com/science/article/pii/S1521694224000573
Galerija slik
Izvleček
Antiphospholipid syndrome (APS) in children is a rare disease associated with significant morbidity and mortality. In comparison with APS in adults, pediatric APS has a more severe presentation with frequent recurrences of thrombotic events and a higher probability of life-threatening catastrophic APS. Nonthrombotic manifestations are also more common in the pediatric age group and can precede thrombosis. New classification criteria have been introduced recently and have not yet been assessed in pediatric patients with APS. In addition to anticoagulation drugs, other novel therapies have emerged including the use of B cell and complement inhibitors, especially in catastrophic APS. The purpose of this review is to provide a broad overview of aPL-related clinical manifestations in pediatric patients based on the analysis of published cohorts and data from the international pediatric APS registry. We also aim to illustrate APS in infants caused by transplacentally transferred maternal aPL, which is very rarely associated with acute thrombotic events in the perinatal period and more frequently with long-term neurodevelopmental abnormalities.
Jezik:
Angleški jezik
Ključne besede:
catastrophic antiphospholipid syndrome
,
children
,
infants antiphospholipid syndrome
,
systemic lupus erythematosus
,
antiphospholipid antibodies
,
thrombosis
,
thrombocytopenia
,
chorea
,
lupus anticoagulants
,
anticardiolipin antibodies
,
anti-β2 glycoprotein I antibodies
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
MF - Medicinska fakulteta
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2024
Št. strani:
15 str.
Številčenje:
Vol. 38, iss. 3, art. 101986
PID:
20.500.12556/RUL-162552
UDK:
61
ISSN pri članku:
1532-1770
DOI:
10.1016/j.berh.2024.101986
COBISS.SI-ID:
204888323
Datum objave v RUL:
25.09.2024
Število ogledov:
123
Število prenosov:
32
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Baillière's best practice and research in clinical rheumatology
Skrajšan naslov:
Baillière's best pract. res. clin. rheumatol.
Založnik:
Elsevier
ISSN:
1532-1770
COBISS.SI-ID:
204885507
Licence
Licenca:
CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:
Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.
Projekti
Financer:
ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:
J3-3061
Naslov:
Klinične, imunološke in genetske značilnosti večorganskega vnetnega sindroma, povezanega s COVID-19, pri otrocih in mladostnikih
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
University Medical Centre Ljubljana
Številka projekta:
20210069
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
University Medical Centre Ljubljana
Številka projekta:
20220090
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj